Key result
Thromboelastometry clotting time (HEPNATEM-CT) appeared more sensitive for detecting in vitro activation of coagulation than activated clotting time in rotary blood pump tests.
Why the study?
In vitro thrombogenicity tests for rotary blood pumps could benefit from assessing coagulation kinematics, prompting evaluation of whether thromboelastometry can assess these kinematics under test conditions.
Does thromboelastometry (TEM) accurately assess coagulation kinematics in vitro during rotary blood pump testing compared to ACT?
Does thromboelastometry (TEM) accurately assess coagulation kinematics in vitro during rotary blood pump testing compared to ACT?
Thromboelastometry clotting time using non-anticoagulated whole blood may be more sensitive than ACT for detecting coagulation activation in in vitro rotary blood pump testing, though standard TEM parameters were uninformative.
In vitro thrombogenicity tests for rotary blood pumps (RBPs) could benefit from assessing coagulation kinematics, as RBP design improves. In this feasibility study, we investigated if the method of thromboelastometry (TEM) is able to assess coagulation kinematics under the in vitro conditions of RBP tests. We conducted in vitro thrombogenicity tests (n=4) by placing Deltastream® DP3 pumps into test loops that were filled with 150 mL of slightly anti-coagulated porcine blood, adjusted to an activated clotting time (ACT) well below clinically recommended levels. Blood samples were taken at certain time points during the experiment until a continuous decrease in pump flow indicated major thrombus formation. Blood samples were analyzed for ACT, platelet count (PLT), and several TEM parameters. While visible thrombus formation was observed in three pumps, ACT indicated an ongoing activation of coagulation, PLT might have indicated platelet consumption. Unexpectedly, most TEM results gave no clear indications. Nonetheless, TEM clotting time obtained by non-anticoagulated and chemically non-activated whole blood (HEPNATEM-CT) appeared to be more sensitive for the activation of coagulation in vitro than ACT, which might be of interest for future pump tests. However, more research regarding standardization of thrombogenicity pump tests is urgently required.
No takes yet. Share an insight, caveat, or question.
Klein et al. (2022) studied In vitro thrombogenicity (n=4). Thromboelastometry (TEM) vs. Activated clotting time (ACT) was evaluated on Coagulation kinematics. Thromboelastometry clotting time (HEPNATEM-CT) appeared more sensitive for detecting in vitro activation of coagulation than activated clotting time in rotary blood pump tests.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: